Mohamed Naem, MD
Gastroenterology · Westlake, OHNPI 1588981195
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $531,952 of the $708,264 with a category attached, or 75.1%. 37 manufacturers reported payments, led by AbbVie at 42.2% of the total. 2025 is the largest year on record at $207,071, 7.6 times the $27,215 reported in 2019. Among gastroenterology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 758 payments — averaging $934.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$299K
- Johnson & Johnson$232K
- Janssen Scientific Affairs, LLC$69K
- Madrigal Pharmaceuticals$66K
- E.r. Squibb & Sons, L.L.C.$25K
- Pfizer$7K
- plus $10K from 31 others
Across 240 payments — averaging $3785.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$734K
- AbbVie$168K
- Pfizer$7K
What the payments were for
- Consulting fees$26,0004%
- Speaking & faculty fees$531,95275%
- Grants$66,0009%
- Travel & lodging$62,1859%
- Food & beverage$22,0993%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 331 | $299,022 |
| Johnson & Johnson | 169 | $231,859 |
| Janssen Scientific Affairs, LLC | 67 | $68,810 |
| Madrigal Pharmaceuticals | 2 | $66,039 |
| E.r. Squibb & Sons, L.L.C. | 18 | $25,488 |
| Pfizer | 26 | $6,958 |
| Bristol Myers Squibb | 22 | $5,443 |
| Janssen Research & Development, LLC | 5 | $1,487 |
| Medtronic(2 entities) | 12 | $631 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $441 |
| Boston Scientific | 6 | $268 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $226 |
| Sanofi | 5 | $195 |
| Phathom Pharmaceuticals, Inc. | 7 | $165 |
| Nestle Healthcare Nutrition Inc. | 9 | $152 |
| Merck | 7 | $140 |
| Gilead | 8 | $132 |
| Shionogi Inc | 1 | $110 |
| Ipsen Biopharmaceuticals, Inc | 4 | $83 |
| UCB, Inc. | 4 | $70 |
| Apollo Endosurgery US Inc | 1 | $69 |
| QOL Medical, LLC | 3 | $60 |
| Intercept Pharmaceuticals, Inc. | 3 | $49 |
| Aimmune Therapeutics, Inc. | 2 | $48 |
| Amgen | 3 | $41 |
| Ardelyx, Inc. | 2 | $38 |
| Redhill Biopharma Inc. | 2 | $36 |
| Celltrion USA Inc. | 2 | $31 |
| Ferring Pharmaceuticals Inc. | 2 | $28 |
| Lilly USA, LLC | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Fresenius Kabi USA, LLC | 1 | $20 |
| Novo Nordisk | 1 | $15 |
| Organon | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$708,264 in reported general payments places this provider in the 95th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $385,843 |
| Skyrizi On-BodyRisankizumab-Rzaa | 15 | $311,351 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 12 | $50,059 |
| MotegrityPrucalopride Succinate | 28 | $17,129 |
| Esomeprazole Magnesium | 19 | $2,983 |
| Dexlansoprazole DrDexlansoprazole | 14 | $2,901 |
| Pantoprazole Sodium | 146 | $1,612 |
| Omeprazole | 19 | $429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $231,859 | $385,84312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $441 | $17,12928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Westlake
- Naim AlkhouriWestlake$1.9M
- Mousab TabbaaWestlake$136K
- Rinjal BrahmbhattWestlake$92K
- Kimberly HarrisWestlake$70K
- Michael SpringerWestlake$68K
- Preeti JhawarWestlake$42K
- Pierre GholamCleveland$1.6M
- Anita AfzaliCincinnati$798K
- Kara de FeliceCincinnati$427K
- Tasos ManokasColumbus$411K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.